Clinical Observation of Modified Buzhong Yiqitang Combined with Erxian Decoction in Treatment of Stress Urinary Incontinence in Perimenopausal Women
10.13422/j.cnki.syfjx.20210833
- VernacularTitle:补中益气汤合二仙汤加减治疗围绝经期妇女压力性尿失禁的临床疗效
- Author:
Yue-fang XU
1
;
Zhao-zhao HUA
2
;
Xiao-yun YAO
1
;
Zhe SUN
1
;
Ting-ting ZHAI
1
Author Information
1. The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine（TCM），Guiyang 550001，China
2. The Second Affiliated Hospital of Guizhou University of TCM，Guiyang 550005，China
- Publication Type:Research Article
- Keywords:
stress urinary incontinence;
perimenopausal period;
spleen and kidney Qi deficiency syndrome;
Buzhong Yiqitang;
Erxian decoction;
sex hormones;
pituitary adenylate cyclase activating peptide;
vasoactive intestinal peptide
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2021;27(23):125-130
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the clinical efficacy of the modified Buzhong Yiqitang combined with Erxian decoction in treating stress urinary incontinence （SUI） of perimenopausal women due to spleen and kidney Qi deficiency. Method:One hundred and six patients were randomly divided into a control group （52 cases） and an observation group（54 cases）. Patients in both groups received lifestyle intervention and pelvic floor muscle training （PFMT）. On this basis， patients in the observation group were further treated with the modified Buzhong Yiqitang combined with Erxian decoction， 1 bag/day， while those in the control group were provided with Suoquan pills， 6 g/time， 2 times/day， for eight weeks. Following the international consultation on incontinence questionnaire-short form （ICIQ-SF） scoring before and after treatment， the urodynamic parameters such as maximum urinary flow rate （Qmax）， maximum urethral closure pressure （MUCP）， residual urine volume （RUV）， abdominal pressure leakage point pressure （ALPP）， and bladder capacity （BC） were measured. The number of incontinence episodes per 24 h， the degree of urinary incontinence， the amount of 1 h urine leakage， and the spleen and kidney Qi deficiency syndrome score were recorded before and after treatment. The levels of estradiol （E2）， follicle stimulating hormone （FSH）， pituitary adenylate cyclase activating peptide （PACAP）， and vasoactive intestinal peptide （VIP） were measured before and after treatment. Result:The ICIQ-SF sub-scores of the urinary incontinence frequency， severity， and impact on quality of life as well as the total score in the observation group were all lower than those in the control group （P<0.01）. Qmax， MUCP， ALPP and BC in the observation group were elevated in contrast to those in control group （P<0.01）， while the RUV declined （P<0.01）. Compared with the control group， the observation group exhibited a decreased number of incontinence episodes per 24 h， milder degree of urinary incontinence， reduced amount of 1 h urine leakage， and lower spleen and kidney Qi deficiency syndrome score （P<0.01）. The E2， PACAP， and VIP in the observation group were up-regulated as compared with those in the control group （P<0.01）， whereas the FSH was down-regulated （P<0.01）. The cure and effective rates of the observation group were （29/50） 58.00% and （47/50）94.00%， respectively， significantly better than （18/48）37.50% and （38/48）79.17% of the control group （χ2=4.124， χ2=4.683， P<0.05）. Conclusion:On the basis of the lifestyle intervention and PFMT， the modified Buzhong Yiqitang combined with Erxian decoction obviously alleviates urinary incontinence， adjusts sex hormones， PACAP and VIP， ameliorates urodynamic parameters， and enhances the quality of life of patients with SUI due to spleen and kidney Qi deficiency. The resulting cure and effective rates are superior to those of the positive control.
